Aim - to investigate the relationship between immunological parameters, level of viral load and severity of morphological changes in the liver according to non-invasive tests in HBeAg-negative patients with chronic hepatitis B. The study included 55 HBeAg-negative patients with chronic hepatitis B. Age of patients was from 20 to 78 years. There were 20 women and 35 men. Quantitative content of HBV-DNA, HBeAg and anti-HBe, TNF-α and IFN-γ was determined in all patients› blood. Statistical processing was performed in Statistica 13 for Windows (StatSoft Inc., No. JPZ804I382130ARCN10-J). The study found an association between HBeAg/anti-HBe seroconversion and severity of liver fibrosis. It is shown that in the presence of liver fibrosis F 2-4 degree the frequency of seroconversion is lower compared with HBeAg-negative patients with F 0-1 (85,7 % vs. 100 %, p <0,05). The association of viral load above HBV-DNA >20000 IU/ml with a high degree of necro-inflammatory activity has also been shown. In HBeAg-negative patients in the presence of activity A 2-3 viral load >20,000 IU/ml is detected in 57,1 % against 20,8 % of patients with A 0-1 (p <0,05). However, it was shown that in HBeAg-negative patients with chronic HBV, TNF-α level in serum, regardless of the severity of morphological changes in the liver is higher, and IFN-γ level is not statistically different from that of healthy people. In HBeAg-negative patients with CHB the detection rate of HBeAg / anti-HBe seroconversion is significantly higher in fibrosis F 0-1. The viral load above the HBV-DNA level>20,000 IU / ml has a relationship with necroinflammatory activity, significantly higher with A 2-3. The TNF-α content is higher than in healthy people (p <0.05), and has no significant relationship with the severity of morphological changes in the liver according to non-invasive tests. The content of IFN-γ in the blood serum of HBeAg-negative patients with CHB does not statistically differ from those of healthy people.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hbeag-negative patients
16
viral load
12
patients chronic
12
chronic hepatitis
12
relationship immunological
8
immunological parameters
8
parameters level
8
level viral
8
load severity
8
severity morphological
8

Similar Publications

Introduction: The minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen (HBsAg) clearance.

Methods: In order to find out the advantaged population, we retrospectively collected 122 CHB patients treated with NAs alone or NAs plus PEG-IFN for 48 weeks, who were admitted to Sun Yat-sen Memorial Hospital from 2019 to 2024.

Results: We found HBsAg clearance rate in NAs plus PEG-IFN group was 40.

View Article and Find Full Text PDF

Coexisting patterns and significance of serum HBV RNA and HBV DNA in patients with treatment-naïve chronic hepatitis B virus infection.

Front Med (Lausanne)

January 2025

Center of Hepatology and Department of Infectious Disease, Jinling Hospital Affiliated to School of Medicine, Nanjing University, Nanjing, China.

Aim: The study aimed to explore the coexisting patterns and assess the significance of serum hepatitis B virus (HBV) RNA and traditional virological biomarkers in patients with antiviral treatment-naïve chronic hepatitis B virus (HBV) infection.

Methods: Serum HBV RNA, HBV DNA, hepatitis B surface antigen (HBsAg), and hepatitis B envelope antigen (HBeAg) levels were measured and compared in patients with chronic hepatitis B virus infection. The HBV RNA levels were determined using a simultaneous amplification and testing assay.

View Article and Find Full Text PDF

Patients with chronic hepatitis B infection (CHB) have an increased risk for death from liver cirrhosis and hepatocellular carcinoma (HCC). In the United States, only an estimated 37% of adults with chronic hepatitis B diagnosis without cirrhosis receive monitoring with at least an annual alanine transaminase (ALT) and hepatitis B deoxyribonucleic acid (DNA), and an estimated 59% receive antiviral treatment when they develop active hepatitis or cirrhosis. A Markov model was used to calculate the costs, health impact and cost-effectiveness of increased monitoring of adults with HBeAg negative inactive or HBeAg positive immune tolerant CHB who have no cirrhosis or significant fibrosis and are not recommended by the current American Association for the Study of Liver Diseases (AASLD) clinical practice guidelines to receive antiviral treatment, and to assess whether the addition of HCC surveillance would be cost-effective.

View Article and Find Full Text PDF

Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB).

Methods: We studied 87 CHB patients with serum HBV DNA levels ≥ 5.

View Article and Find Full Text PDF

Objectives: There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF).

Methods: A total of 805 HBeAg-negative patients without cirrhosis receiving entecavir (n=406), TDF (n=260) or TAF (n=139) were enrolled. Propensity-score (PS) matching method was applied to eliminate the significant differences in clinical characteristics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!